Your browser does not support iframes.
Jerusalem, September 14, 2017 – In 2016, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) engaged more than 300,000 people in 35 countries in programs aimed to help and empower patients as they deal with their illnesses. These patient support programs are among the outcomes of broader efforts aimed to better understand and support patient needs and are covered in Teva’s 2016 Social Impact Report. Released today, the report provides an overview of the company’s progress toward delivering affordable medicines to patients around world and reflects the company’s continued efforts to integrate Corporate Social Responsibility into its business practices. Among other efforts to fulfill its ambition as a socially and environmentally responsible company, Teva contributed $48.4 million in 28 countries to support patients and communities, responded rapidly to drug shortages in several countries and provided rare medicines to enable organ transplants and prevent the spread of multidrug-resistant tuberculosis in countries who could otherwise not afford such drugs. Teva also continued to encourage diverse talent by maintaining a gender-equal global network of employees, with women representing 47% of the global workforce and 49% of managers.“People are at the heart of everything we do. Our purpose is to improve health wherever we are,” said Iris Beck-Codner, Group Executive Vice President for Corporate Reputation at Teva. “We are committed to living this purpose every day by discovering new treatments, offering more convenient care, helping communities in times of need and making medicines more accessible and affordable. As one of the world’s leading pharmaceutical companies, our goal is to make a positive impact far beyond medicines—improving lives and communities across the globe by threading societal and environmental good into the fabric of our business.”
Additional Highlights of Teva’s efforts in 2016 include:
With the world’s largest medicine cabinet with a unique specialty portfolio, Teva is committed to making treatments more accessible and affordable for patients, caregivers and healthcare professionals, while addressing future health needs in a responsible, sustainable way.
To download Teva’s Social Impact efforts, please visit, http://tevapharm.com/files/docs/Teva_2016_Social_Impact_Report.pdf
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva’s net revenues in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the potential benefits and commercialization of Fremanezumab, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: the uncertainty of commercial success of Fremanezumab; challenges inherent in product research and development, including uncertainty of obtaining regulatory approvals; our specialty medicines business, including: competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights; our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain;
disruptions of our or third party information technology systems or breaches of our data security; the restructuring of our manufacturing network, including potential related labor unrest; the impact of continuing consolidation of our distributors and customers; and variations in patent laws that may adversely affect our ability to manufacture our products; compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks; and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.